At the end of the same year, Curigliano and collaborators published a series of 2130 T1ab breast cancer patients—150 (7%) with HER-2+—looked at the prognostic role of HER-2 status for small tumours [25]. This evidence concerns the gene ERBB2 and breast carcinoma.